Parallel Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Parallel Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$322	Sell	13 -20	-61%	-$476	﹤0.01%	3732
2025 Q4	$770	Buy	33 +20	+154%	+$446	﹤0.01%	3343
2025 Q3	$256	Sell	13 -43	-77%	-$884	﹤0.01%	3417
2025 Q2	$1.22K	Buy	56 +29	+107%	+$685	﹤0.01%	3162
2025 Q1	$655	Hold	27	–	–	﹤0.01%	3198
2024 Q4	$563	Buy	27 +14	+108%	+$301	﹤0.01%	3202
2024 Q3	$258	Hold	13	–	–	﹤0.01%	3261
2024 Q2	$201	Hold	13	–	–	﹤0.01%	3204
2024 Q1	$207	Hold	13	–	–	﹤0.01%	3146
2023 Q4	$219	Hold	13	–	–	﹤0.01%	3160
2023 Q3	$152	Sell	13 -140	-92%	-$1.87K	﹤0.01%	3256
2023 Q2	$2.06K	Hold	153	–	–	﹤0.01%	2744
2023 Q1	$2.54K	Hold	153	–	–	﹤0.01%	2681
2022 Q4	$2.85K	Hold	153	–	–	﹤0.01%	2546
2022 Q3	$2K	Buy	+153	New	+$1.81K	﹤0.01%	2617
2021 Q1	–	Sell	-2	Closed	–	–	2806
2020 Q4	$0	Buy	+2	New	+$7	﹤0.01%	2584

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Parallel Advisors's CPRX Position: Q1 2026 in Review

Parallel Advisors reduced its Catalyst Pharmaceutical (CPRX) stake by 61% in Q1 2026, selling an estimated $476 and leaving 13 shares worth $322. The position accounts for ﹤0.01% of the portfolio, ranked #3732.

Parallel Advisors first reported a position in CPRX in Q4 2020 and has held it in 16 quarters since. The position peaked at $2.85K in Q4 2022. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

Parallel Advisors held 13 shares of Catalyst Pharmaceutical worth $322 as of Q1 2026.
Parallel Advisors sold 20 Catalyst Pharmaceutical shares in Q1 2026, an estimated $476.
Catalyst Pharmaceutical made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #3732 holding.
Parallel Advisors first reported a position in Catalyst Pharmaceutical in Q4 2020 and has held it in 16 quarters since.
Parallel Advisors's Catalyst Pharmaceutical position peaked at $2.85K in Q4 2022.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.